FI972654L - Meletsitoosia laimentimena sisältävät jauhekoostumukset - Google Patents

Meletsitoosia laimentimena sisältävät jauhekoostumukset Download PDF

Info

Publication number
FI972654L
FI972654L FI972654A FI972654A FI972654L FI 972654 L FI972654 L FI 972654L FI 972654 A FI972654 A FI 972654A FI 972654 A FI972654 A FI 972654A FI 972654 L FI972654 L FI 972654L
Authority
FI
Finland
Prior art keywords
meletzitose
diluent
compositions containing
powder compositions
powder
Prior art date
Application number
FI972654A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972654A7 (fi
FI972654A0 (fi
Inventor
Kjell Baeckstroem
Ann Johansson
Helena Linden
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI972654A7 publication Critical patent/FI972654A7/fi
Publication of FI972654A0 publication Critical patent/FI972654A0/fi
Publication of FI972654L publication Critical patent/FI972654L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
FI972654A 1994-12-22 1995-12-19 Meletsitoosia laimentimena sisältävät jauhekoostumukset FI972654L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9404468A SE9404468D0 (sv) 1994-12-22 1994-12-22 Powder formulations
PCT/SE1995/001541 WO1996019207A1 (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent

Publications (3)

Publication Number Publication Date
FI972654A7 FI972654A7 (fi) 1997-06-19
FI972654A0 FI972654A0 (fi) 1997-06-19
FI972654L true FI972654L (fi) 1997-06-19

Family

ID=20396435

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972654A FI972654L (fi) 1994-12-22 1995-12-19 Meletsitoosia laimentimena sisältävät jauhekoostumukset

Country Status (33)

Country Link
US (1) US6004574A (pl)
EP (2) EP0799030B1 (pl)
JP (1) JPH10510828A (pl)
KR (1) KR100391873B1 (pl)
CN (1) CN1080114C (pl)
AR (1) AR002261A1 (pl)
AT (2) ATE220900T1 (pl)
AU (1) AU702898B2 (pl)
BR (1) BR9510422A (pl)
CA (1) CA2206803A1 (pl)
CZ (1) CZ288487B6 (pl)
DE (2) DE69533294T2 (pl)
DK (2) DK0799030T3 (pl)
EE (1) EE03381B1 (pl)
ES (2) ES2222306T3 (pl)
FI (1) FI972654L (pl)
HU (1) HU217975B (pl)
IL (1) IL116459A (pl)
IS (1) IS1848B (pl)
MY (1) MY114211A (pl)
NO (1) NO315966B1 (pl)
NZ (1) NZ298168A (pl)
PL (1) PL183944B1 (pl)
PT (2) PT1224929E (pl)
RU (1) RU2144819C1 (pl)
SA (1) SA95160484B1 (pl)
SE (1) SE9404468D0 (pl)
SK (1) SK283147B6 (pl)
TR (1) TR199501632A1 (pl)
TW (1) TW474823B (pl)
UA (1) UA44757C2 (pl)
WO (1) WO1996019207A1 (pl)
ZA (1) ZA9510753B (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
WO1996019198A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol drug formulations
ATE219942T1 (de) * 1997-03-20 2002-07-15 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
JP2002541213A (ja) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
WO2002011695A2 (en) * 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
CA2466982A1 (en) 2001-11-19 2003-05-30 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
CN101618023B (zh) * 2008-06-30 2011-11-30 江苏先声药物研究有限公司 一种制备微粉化蛋白的方法
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
CN103003422B (zh) 2010-04-20 2015-02-11 奥克塔法马股份有限公司 用于药物蛋白的新型稳定剂
DK3415139T3 (da) 2011-06-14 2022-06-20 Neurelis Inc Administration af benzodiazepin
US9480966B2 (en) * 2012-04-30 2016-11-01 General Electric Company Substrates and methods for collection, stabilization and elution of biomolecules
WO2015146849A1 (ja) * 2014-03-25 2015-10-01 国立大学法人香川大学 希少糖を有効成分とするマラリア伝播阻止剤およびマラリア原虫の発育阻害剤
JP2017524379A (ja) * 2014-06-30 2017-08-31 テイト アンド ライル イングレディエンツ アメリカス リミテッド ライアビリティ カンパニーＴａｔｅ ＆ Ｌｙｌｅ Ｉｎｇｒｅｄｉｅｎｔｓ Ａｍｅｒｉｃａｓ Ｌｌｃ 消耗品用コーティング組成物
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
EP3754011B1 (en) 2015-09-09 2022-02-16 Drawbridge Health, Inc. Devices for sample collection, stabilization and preservation
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
US12599611B2 (en) 2021-06-10 2026-04-14 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
CN117327132B (zh) * 2023-10-08 2025-08-08 新疆医科大学 刺糖松三糖及其提取工艺和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (pl) * 1957-01-31 1957-04-11
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) * 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DE3326089A1 (de) * 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
EP0223831B1 (en) * 1985-05-22 1992-07-15 Liposome Technology, Inc. Liposome inhalation method and system
DE3532074A1 (de) * 1985-09-09 1987-03-12 Berlin Chemie Veb Resorptionsvermittler fuer biologisch aktive peptide
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
SU1672627A1 (ru) * 1988-06-06 1995-11-10 Институт технической теплофизики АН УССР Способ получения порошка ампиокса натрия
EP0360340A1 (en) * 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
NZ241954A (en) * 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
JPH07503154A (ja) * 1992-01-21 1995-04-06 エス・アール・アイ・インターナシヨナル 微細化ポリペプチド薬剤の改良調製方法
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation

Also Published As

Publication number Publication date
AU4359296A (en) 1996-07-10
TW474823B (en) 2002-02-01
KR100391873B1 (ko) 2003-10-17
DE69533294T2 (de) 2005-05-19
JPH10510828A (ja) 1998-10-20
FI972654A7 (fi) 1997-06-19
CA2206803A1 (en) 1996-06-27
PT1224929E (pt) 2004-10-29
IS4495A (is) 1997-06-03
IS1848B (is) 2003-02-07
ES2222306T3 (es) 2005-02-01
DE69527542T2 (de) 2003-01-30
SA95160484B1 (ar) 2005-10-01
EE9700135A (et) 1997-12-15
DK1224929T3 (da) 2004-10-04
ATE271382T1 (de) 2004-08-15
HK1003619A1 (en) 1998-11-06
CN1080114C (zh) 2002-03-06
FI972654A0 (fi) 1997-06-19
HU217975B (hu) 2000-05-28
CZ288487B6 (en) 2001-06-13
MX9704551A (es) 1997-10-31
SK283147B6 (sk) 2003-03-04
EP1224929A2 (en) 2002-07-24
NO972660L (no) 1997-06-10
TR199501632A1 (tr) 1997-03-21
EP0799030B1 (en) 2002-07-24
SE9404468D0 (sv) 1994-12-22
ATE220900T1 (de) 2002-08-15
HUT77648A (hu) 1998-07-28
DE69533294D1 (de) 2004-08-26
US6004574A (en) 1999-12-21
NO315966B1 (no) 2003-11-24
ES2177674T3 (es) 2002-12-16
SK81297A3 (en) 1997-11-05
RU2144819C1 (ru) 2000-01-27
MY114211A (en) 2002-08-30
AU702898B2 (en) 1999-03-11
EE03381B1 (et) 2001-04-16
BR9510422A (pt) 1998-07-07
DK0799030T3 (da) 2002-09-16
NO972660D0 (no) 1997-06-10
PL183944B1 (pl) 2002-08-30
AR002261A1 (es) 1998-03-11
UA44757C2 (uk) 2002-03-15
IL116459A (en) 2002-11-10
DE69527542D1 (de) 2002-08-29
CN1171049A (zh) 1998-01-21
WO1996019207A1 (en) 1996-06-27
PL320751A1 (en) 1997-10-27
EP1224929A3 (en) 2002-12-18
IL116459A0 (en) 1996-03-31
EP1224929B1 (en) 2004-07-21
PT799030E (pt) 2002-11-29
CZ194697A3 (en) 1997-10-15
EP0799030A1 (en) 1997-10-08
NZ298168A (en) 1999-08-30
ZA9510753B (en) 1996-06-24

Similar Documents

Publication Publication Date Title
FI972654A0 (fi) Meletsitoosia laimentimena sisältävät jauhekoostumukset
FI961436L (fi) Suun kautta annettavia sienilääkekoostumuksia
DE69423670D1 (de) Siloxy-aluminoxan-Zusammensetzungen
EP0509717A3 (en) New herbicidal compositions
ZA944543B (en) Fungicidal compositions
HRP950568B1 (en) Novel herbicidal compositions
GB9304294D0 (en) Herbicidal compositions
GB9424853D0 (en) New herbicidal compositions
ZA944565B (en) Herbicidal compositions
GB2289843B (en) Herbicidal compositions
HU9400963D0 (en) Fungicidal compositions
GB2308301B (en) New fungicidal compositions
GB9413813D0 (en) Herbicidal compositions
GB9510328D0 (en) Compositions containing zirconium compounds
ZA914247B (en) Herbicidal compositions
ZA957012B (en) Novel compositions
GB9419401D0 (en) Herbicidal compositions
GB9419400D0 (en) Herbicidal compositions
GB9403581D0 (en) Novel compositions
GB9405681D0 (en) Novel compositions
GB9406080D0 (en) Novel compositions
GB9405682D0 (en) Novel compositions
GB9412724D0 (en) Novel compositions
GB9410247D0 (en) Novel compositions
GB9424346D0 (en) Novel compositions